In China Hearing, Commissioners Ask About Investor Risk But Witnesses Urge Caution
The U.S. China Economic and Security Review Commission hears from three witnesses who say don’t pick on China when it’s down.
The TSP’s Mutual Fund Window is a Back Door for Chinese Stocks
By Robby Stephany Saunders The Chinese language abounds with timeless proverbs, but “don’t bite the hand that feeds you” is not one of them. Shortly
Reuters/Ipsos Poll: Yes, Tariff China More, Big Majority Say
Some 66% of Americans say we should keep tariffs on China.
As June Trade Deficit Falls, U.S. Still On Track to Repeat $1 Trillion Trade Gap with World
The June deficit fell for the second month in a row, but that doesn’t mean the U.S. is not on track for another trillion-dollar trade gap with the world. China remains largest single source of the trade deficit.
Senate Amendment in Defense Act Puts Restrictions on Outbound Investment into China Tech
This summer saw a host of amendments in defense bills to restrict investment in China. Will the rhetoric be met with action?
Latest China Company on Uyghur Law’s Banned List Counts USAA As Investor
China companies are put on Entity Lists for being in breach of certain laws. In this case, allegations of forced labor. That doesn’t stop U.S. investors from buying their stocks.
Majority of Senate Votes to Prohibit Federal Retirement Savings from Funding China
The majority of the Senate supports this legislation, and we will be working with lawmakers in the House to ensure this bill becomes law.
Inflation Reduction Act Brings Solar Investments to the US. WSJ Unimpressed.
Companies continue to invest in domestic solar thanks to all the new renewable energy tax credits. Without them, and tariffs, US solar would be China owned.
Venture Capital CEO Tells House Committee He Agrees With Outbound Investment Restrictions
In latest House Select Committee on the CCP, outbound investment restrictions get favorable view.
Candidate Trump Announces Plans to Reshore Essential Medicines to Avoid Drug Shortages
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
